Brodalumab: First Global Approval

Brodalumab: First Global Approval

Brodalumab (Lumicef ® ) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs (New York, N.Y.) N.Y.), 2016-09, Vol.76 (14), p.1403-1412
1. Verfasser: Greig, Sarah L.
Format: Artikel
Sprache:eng
Schlagworte:
AdisInsight Report
Agreements
Antibodies, Monoclonal - therapeutic use
Asthma
Cytokines
Dermatology
Humans
Internal Medicine
Japan
Marketing
Medicine
Medicine & Public Health
Monoclonal antibodies
Patients
Pharmacology/Toxicology
Pharmacotherapy
Psoriasis
Psoriasis - drug therapy
Psoriatic arthritis
Receptors, Interleukin-17 - metabolism
Rheumatoid arthritis
Suicidal behavior
Suicides & suicide attempts
Tuberculosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Brodalumab (Lumicef ® ) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family. Regulatory applications for brodalumab in plaque psoriasis are also under review in the USA, EU and Canada. This article summarizes the milestones in the development of brodalumab leading to this first approval for the treatment of psoriasis.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-016-0634-8